Insight Holdings Group LLC Purchases 76,139 Shares of Kyverna Therapeutics, Inc. $KYTX

Key Points

• Insight Holdings Group LLC increased its stake in Kyverna Therapeutics by 8.3%, acquiring an additional 76,139 shares, bringing its total ownership to 989,054 shares, valued at approximately $1.9 million.
• Recent analyst activity shows a positive outlook for Kyverna Therapeutics, with a consensus rating of "Buy" and a target price increase from $5.00 to $10.00.
• Despite this, Kyverna Therapeutics' stock experienced a decline of 2.4%, trading at $3.63 with a market capitalization of $157 million.

Insight Holdings Group LLC increased its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 8.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 989,054 shares of the company's stock after purchasing an additional 76,139 shares during the quarter. Kyverna Therapeutics makes up 0.1% of Insight Holdings Group LLC's investment portfolio, making the stock its 25th largest holding. Insight Holdings Group LLC owned approximately 2.29% of Kyverna Therapeutics worth $1,909,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Peapod Lane Capital LLC acquired a new stake in Kyverna Therapeutics in the 1st quarter worth approximately $765,000. Two Sigma Investments LP lifted its holdings in Kyverna Therapeutics by 47.9% in the 4th quarter. Two Sigma Investments LP now owns 181,654 shares of the company's stock worth $679,000 after purchasing an additional 58,800 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Kyverna Therapeutics by 2,225.0% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 461,959 shares of the company's stock worth $1,728,000 after purchasing an additional 442,090 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Kyverna Therapeutics by 53.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company's stock worth $53,000 after purchasing an additional 4,990 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Kyverna Therapeutics by 65.4% in the 4th quarter. BNP Paribas Financial Markets now owns 44,983 shares of the company's stock worth $168,000 after purchasing an additional 17,786 shares during the last quarter. 18.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KYTX has been the subject of several analyst reports. William Blair started coverage on Kyverna Therapeutics in a report on Wednesday, August 20th. They issued an "outperform" rating for the company. HC Wainwright upped their price target on Kyverna Therapeutics from $5.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, August 29th. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $16.60.

Kyverna Therapeutics Price Performance

Shares of KYTX traded down $0.10 on Wednesday, reaching $4.01. 172,969 shares of the stock traded hands, compared to its average volume of 361,655. The firm has a market cap of $173.20 million, a price-to-earnings ratio of -1.09 and a beta of 3.07. Kyverna Therapeutics, Inc. has a 12 month low of $1.78 and a 12 month high of $7.39. The stock's 50-day moving average price is $3.62 and its 200-day moving average price is $2.87.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.00) by $0.03. As a group, equities research analysts forecast that Kyverna Therapeutics, Inc. will post -3.29 earnings per share for the current fiscal year.

Kyverna Therapeutics Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.